Atrinsic Inc. (ATRN) security traded over $6.6M in dollar volume as of 2 p.m. EST
ATRN stock makes unbeatable run since cent level on January 2012
469 7th Avenue
New York, NY 10018
Atrinsic, Inc. operates as a direct to consumer Internet marketing company. The company sells entertainment and lifestyle subscription products direct to consumers through the Internet.
Freddie Mac (FMCC) announced today that it auctioned a $500 million reopening of its 3.75% seven-year USD Reference Notes security that matures on March 27 , 2019. The stop yield for the issue, CUSIP 3137EACA5, was 1.557%, priced at 114.712429, or approximately22.7 basis points more than seven-year U.S. Treasury Notes. The bid-to-cover ratio was4.02 to 1.
After the reopening, which was conducted via an Internet-based auction, the outstanding size of the 3.75% seven-year Reference Notes security will be $4.0 billion . The issue will settle on Thursday, February 16, 2012 , and is listed on the Euro MTF market of the Luxembourg Stock Exchange . All auction details can be found on Freddie Mac ‘s Debt Securities Web page .
Fannie Mae (FNMA) has been followed this news.
Investor Relations Department
1551 Park Run Drive, MS D5F
McLean, VA 22102-3110
In 1970, Congress created Freddie Mac with a few important goals in mind:
- Make sure that financial institutions have mortgage money to lend
- Make it easier for consumers to afford a decent house or apartment
- Stabilize residential mortgage markets in times of financial crisis
To fulfill this mission, Freddie Mac conducts business in the U.S. secondary mortgage market – meaning we do not originate loans – and works with a national network of mortgage lending customers. We have three business lines: a Single Family Credit Guarantee business for home loans; a Multifamily business for apartment financing; and an investment portfolio.
InVivo Therapeutics (NVIV) stock traded $1.6M as of 2pm EST within daily range from $2.62 to $2.80. Email to subscribers from February 13th available at this link
One Broadway, 14th Floor
Cambridge, MA 02142
InVivo Therapeutics Corporation is a Cambridge, MA based medical device company founded to develop and commercialize groundbreaking technologies for the treatment of spinal cord injuries (SCI).
Currently, there are no treatment options for SCI patients to successfully restore function following a spinal cord injury. Existing treatments consist of a collection of approaches that only focus on symptoms of SCI, such as decompression and mechanical stabilization of the spinal cord, rather than on the underlying pathology.